Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Anlotinib in Advanced NSCLC
NCT04507906Phase 2Completed
- Sponsor
- Shanghai Chest Hospital
- Start
- Nov 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, nivolumab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Started Nov 2020; status: completed.
02
Drugs
anlotinibnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04507906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04507906.